Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis Extension Study in ATTR-CM
NCT02791230Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2016
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Pfizer. Primary endpoints: Time to All-Cause Mortality up to 91 months, Number of Participants With All-Cause Mortality Events up to 61 months and 1 more. Started Jun 2016; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT02791230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02791230.